Catumaxomab Approved by European Commission for Intraperitoneal Treatment of Malignant Ascites induced by EpCAM-positive carcinomas

Catumaxomab (Korjuny) has been approved by European Commission for the intraperitoneal treatment of malignant ascites in adult with EpCAM-positive carcinomas who are not eligible for further systemic anticancer therapy, filling a significant gap in this untapped market.

Catumaxomab has received the positive opinion from CHMP in the European Union

Approved for cancer treatment in 2009, KORJUNY® (Catumaxomab) will soon receive again its approval in Europe for the indication of malignant ascites. As a pioneering treatment, Catumaxomab stands out as the first trifunctional T cell engager antibody and the first drug in the world approved specifically for the treatment of MA. Impressively, it has demonstrated safety and anti-tumor efficacy in ~3000 patients.

LintonPharm to Release Data on Catumaxomab for Advanced Gastric Cancer with Peritoneal Metastasis at 2022 ASCO Annual Meeting

The preliminary results of Catumaxomab for advanced gastric cancer with peritoneal metastasis is published online at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

LintonPharm Announces Completion of Enrollment for Stage 1 of the Global Phase Ⅲ Trial of Catumaxomab in Patients with Advanced Gastric Cancer

LintonPharm has completed the enrollment of stage 1 of the global phase III trial. This trial evaluates the safety and efficacy of Catumaxomab, a bispecific monoclonal antibody, in adult patients with advanced Gastric Cancer with Peritoneal Carcinomatosis.

LintonPharm Announces First Patient Dosed in Phase Ⅰ/Ⅱ Clinical Trial of Catumaxomab for Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

The first patient has been dosed in the Phase Ⅰ/Ⅱ clinical trial program for catumaxomab , a monoclonal bispecific antibody being studied for the treatment of Non-Muscle-Invasive Bladder Cancer unresponsive to Bacillus Calmette-Guerin.